Microbiome Therapeutics Market Growth Prospects, Trends and Forecast up to 2030

According to Nova one advisor, the global Microbiome Therapeutics market was valued at USD 100.4 million in 2021 and it is expected to hit around USD 973.75 million by 2030 with a CAGR of 31.40% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7470

Key Takeaways:

• By type, the FMT segment held the largest market share in 2021 owing to its use as a therapeutic option in the treatment of recurrent C. difficile infection
• By application, the C. difficile segment held the largest share due to the use of microbiome therapeutics in the treatment of recurrent infections
• North America dominated the global market in 2021 and is anticipated to be the fastest growing region owing to the high adoption rate of novel therapeutics and the presence of regulatory support
• Partnerships between big pharma companies and smaller companies that are developing microbiome therapeutics are highly common which allows these companies to receive funding and use the expertise of big pharma these companies
• Key market players include OpenBiome, Seres Therapeutics Inc., 4D Pharma Plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., and Vedanta Bioscience, Inc.

The rise in prevalence of target diseases such as gastrointestinal diseases, diabetes, and immunological indications is anticipated to drive growth. The adoption of fecal microbial transplant and the availability of FMT in form of capsules has enhanced the acceptance of microbiome therapeutics amongst patients with C. difficile infection. Furthermore, increasing R&D investments and government support are anticipated to further drive the market.

FMT has demonstrated a considerable success rate in the treatment of patients with recurrent C. difficile infection. Thus, the growing prevalence of the condition is expected to escalate the demand for microbiome therapies. For instance, as per Therapeutic Advancements in Gastroenterology Journal, in 2022, after initial occurrence, 25-65% of the patients in the U.S. experience recurrent CDI which makes the treatment complex.

There has been increasing demand to understand the human microbiome to be able to transform the potential of the microbiome for use in therapeutics. This has led to an increase in R&D which has been driving the presence of a stronger pipeline in the market. Candidates such as CH-0601, and M-008 are under development for diabetes treatment. Moreover, companies are receiving heightened funding from investors owing to enhanced interest in the field. For instance, in July 2021, Vedanta Biosciences received funding of USD 68 million for phase III development of its product VE303 for high-risk CDI treatment.

Key players operating in the global market are engaged in extensive research to gain an advantage over other players. The companies are engaged in taking efforts to develop and manufacture products to be used for therapies. Numerous products are in the initial stages of trials and are expected to be developed and used in the market. For instance, in 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III data of their candidate RBX2660 for the reduction in recurring C. difficile infection. The candidate further has a fast track, orphan, and breakthrough therapy designations from the FDA.

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7470

Report Scope of the Microbiome Therapeutics Market

Type Insights

Fecal microbiota therapy (FMT) dominated the microbiome therapeutics market in 2021 with a share of 100%. The dominance of the segment is attributed to its wide usage in the treatment of C. difficile infection. Moreover, increasing R&D focusing on developments to discover other therapeutic applications of FMT and the introduction of capsules in the market is expected to drive the growth. For instance, in February 2021, new direct testing for SARS-COV-2 was announced by OpenBiome in fecal microbiota therapy preparation which is aimed at increasing the availability of FMT to any scheduled patient for emergency use without infection transmission risk.

Application Insights

Clostridium difficileinfection (CDI or C. difficile) application segment is projected to expand at the fastest growth rate with a CAGR of 33.79% from 2022 to 2030. The growth of this segment is attributed to the increasing use of Fecal microbiota transplants (FMT) in the treatment of C. difficile. According to a study published in 2020, by the University of Birmingham, FMT is highly accepted for the treatment of patients suffering from Clostridium difficile infections. Further, FMT is more efficient in the treatment of C difficile than an antibiotic, especially in recurrent cases.

Crohn’s disease application segment is expected to show lucrative growth during the forecast period owing to enhanced focus on gut microbial changes in patients with the condition. For instance, as per the Microbiome Journal in 2020, remission of Crohn’s disease can be maintained in patients with the use of fecal microbiota transplantation.

Regional Insights

North America dominated the market with the largest market share of 74.27% in 2021. Highly established research facilities for the development of novel therapeutics and increasing target population are the major factors for the dominance of the region. Further, the prevalence of programs such as the Canadian Microbiome Initiative (CMI) in Canada facilitates collaboration with stakeholders and partners. This allows the focusing of research efforts on microbiome therapeutics development. For instance, in July 2021, Biocodex Microbiota Foundation announced a call for proposals for microbiome studies in Canada for over USD 26,000 in research grants. These grants are expected to fuel new developments in the market.

Europe is estimated to demonstrate significant growth during the forecast period. Germany is an emerging market in Europe for microbiome therapeutics. Despite the high cost of microbiome therapeutics, supportive reimbursement policies are expected to facilitate treatment adoption in upcoming years. Furthermore, startups are receiving funding to research and introduce microbiome-based products.

Some of the prominent players in the Microbiome Therapeutics Market include:

• OpenBiome
• Seres Therapeutics Inc.
• 4D Pharma plc.
• Locus Biosciences, Inc.
• Enterome SA
• Finch Therapeutics Group, Inc.
• Intralytix, Inc.
• Microbiotica
• Second Genome
• Rebiotix Inc.
• Vedanta Bioscience, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Microbiome Therapeutics market

• Type
  • FMT
  • Microbiome Drugs
• Application
  • C. difficile
  • Crohn’s disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7470

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/